BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T172518
CREATED:20201022T103840Z
LAST-MODIFIED:20201022T104916Z
UID:27595-1615248000-1615507199@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders 2021
DESCRIPTION:2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program\, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field\, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market. \n \nThe 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021\, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia\, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality. \nTo know more about Gene Therapy for Blood Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210313
DTSTAMP:20260515T172518
CREATED:20210226T095658Z
LAST-MODIFIED:20210226T100244Z
UID:29127-1615420800-1615593599@www.pharmajournalist.com
SUMMARY:2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference
DESCRIPTION:The Diagnostics sector has emerged as a prominent game changer in healthcare\, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions\, it needs to be quicker\, précised\, and accurate. \nPoint-of-care testing (POCT) is a growing testing. Today\, you may see POCT in a hospital with handheld gadgets or small testers in emergency department\, extensive care setting\, popular clinical wards\, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient’s point of care. \n \nIn the era of improved diagnostics\, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional\, Industrial specialists\, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool. \nEvent Website: https://bit.ly/3gNnkOq \nRegistration link: https://bit.ly/3oRX7kH
URL:https://www.pharmajournalist.com/event/2nd-annual-marketsandmarkets-infectious-disease-diagnostics-and-point-of-care-testing-virtual-conference/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T172518
CREATED:20210226T105316Z
LAST-MODIFIED:20210226T111537Z
UID:29175-1615420800-1615507199@www.pharmajournalist.com
SUMMARY:MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
DESCRIPTION:High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event \nThe end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy\, Gene Therapy\, Monoclonal Antibodies\, Vaccines\, biosimilars and biobetters\, plasma therapy as well as others. \nA host of attractive\, high growth opportunities such as single use systems\, Lab Scale and CGMP manufacturing and R&D\, Crispr and other Gene editing tools and technologies\, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs\, CMOs\, Bioprocess solutions manufacturers\, Biobanks\, automation technology providers etc can benefit from this unprecedented growth over the next 5 years. \nThis Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem\, as seen through the lens of eminent CXOs in this space \nEvent Website: https://bit.ly/3qJYdQF  \nRegistration link: https://bit.ly/2Mcpg8i 
URL:https://www.pharmajournalist.com/event/marketsandmarkets-biopharma-manufacturing-crystal-ball-event-time-zone-9am-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
END:VCALENDAR